Unraveling the Role of Huntingtin in Breast Cancer Metastasis.

BACKGROUND Huntingtin (HTT) is mutated in Huntington's disease but is ubiquitously expressed, and mutant HTT influences cancer progression. We investigated wild-type HTT function during breast cancer. METHODS We analyzed HTT and ZO1 expression as well as the HTT phosphoserine 421-activated form (S421-P-HTT) in human breast cancer tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. We performed in vitro migration and invasion assays as well as in vivo tail vein injections of the metastatic 4T1 cells in BALB/c mice (n = 11 per group). We analyzed tumor progression in knock-in mice with modified S421 crossed with the MMTV-PyVT mammary cancer model (at least n = 12 per group). Data were analyzed with unpaired t tests, analysis of variance, Pearson or Spearman correlation, and Mann Whitney or Kruskal-Wallis tests. All statistical tests were two-sided. RESULTS Levels of HTT and of S421-P-HTT are abnormally low in poorly differentiated and metastatic human breast cancers. HTT expression is downregulated in invasive compared with in situ carcinoma (P < .001). In BALB/c mice, silencing of HTT promotes lung colonization by a metastatic mammary cancer cell line (P = .005) and S421-unphosphorylatable-HTT accelerates cancer progression. HTT interacts with ZO1 and regulates both its expression and its localization to tight junctions. In human breast tumors, the patterns of HTT and ZO1 expression are similar (Pearson correlation coefficient = 0.66, P < .001). CONCLUSIONS HTT may inhibit breast tumor dissemination through maintenance of ZO1 at tight junctions. Downregulation of HTT transcript and protein levels is a prognostic factor for poor prognosis and metastasis development.

[1]  S. Vacher,et al.  Quantification of PKC family genes in sporadic breast cancer by qRT‐PCR: Evidence that PKCι/λ overexpression is an independent prognostic factor , 2012, International journal of cancer.

[2]  J. Gusella,et al.  An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin , 2012, Nature Neuroscience.

[3]  László Harsányi,et al.  Expression of Tight Junction Molecules in Breast Carcinomas Analysed by Array PCR and Immunohistochemistry , 2012, Pathology & Oncology Research.

[4]  S. Humbert,et al.  Huntingtin: here, there, everywhere! , 2013, Journal of Huntington's disease.

[5]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[6]  D. Allred,et al.  Loss of Par3 promotes breast cancer metastasis by compromising cell–cell cohesion , 2012, Nature Cell Biology.

[7]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[8]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[9]  A. Levine,et al.  p53 tumor suppressor protein regulates the levels of huntingtin gene expression , 2006, Oncogene.

[10]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[11]  I. Treilleux,et al.  Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer , 2008, Proceedings of the National Academy of Sciences.

[12]  I. Bièche,et al.  Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. , 2001, Oncogene.

[13]  M. Gorospe,et al.  JunD represses transcription and translation of the tight junction protein zona occludens-1 modulating intestinal epithelial barrier function. , 2008, Molecular biology of the cell.

[14]  Cam Patterson,et al.  The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus , 2011, PloS one.

[15]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[16]  S. Humbert,et al.  Huntingtin Is Required for Epithelial Polarity through RAB11A-Mediated Apical Trafficking of PAR3-aPKC , 2015, PLoS biology.

[17]  I. Bièche,et al.  Quantification of estrogen receptor α and β expression in sporadic breast cancer , 2001, Oncogene.

[18]  P. Bryant,et al.  Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. , 1998, The American journal of pathology.

[19]  M. Bissell,et al.  The Organization of Tight Junctions in Epithelia: Implications for Mammary Gland Biology and Breast Tumorigenesis , 2003, Journal of Mammary Gland Biology and Neoplasia.

[20]  W. Jiang,et al.  Loss of tight junction barrier function and its role in cancer metastasis. , 2009, Biochimica et biophysica acta.

[21]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[22]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[24]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[25]  S. Tezenas du Montcel,et al.  The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling , 2013, EMBO molecular medicine.

[26]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[27]  S. Humbert,et al.  Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease , 2009, Molecular Brain.

[28]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[29]  A. Funnell,et al.  Holding Tight: Cell Junctions and Cancer Spread. , 2012, Trends in cancer research.

[30]  Aamir Ahmad,et al.  The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis , 2012, International journal of molecular sciences.

[31]  S. Humbert,et al.  Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons , 2008, The EMBO journal.

[32]  N. Déglon,et al.  Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421 , 2006, The Journal of Neuroscience.

[33]  S. Humbert,et al.  pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking , 2010, Molecular Brain.

[34]  C. Croce,et al.  Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.

[35]  B. Dutrillaux,et al.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. , 2007, Cancer research.

[36]  S. Humbert,et al.  Huntingtin Regulates Mammary Stem Cell Division and Differentiation , 2014, Stem cell reports.

[37]  D. Mu,et al.  Tight junction proteins: from barrier to tumorigenesis. , 2013, Cancer letters.

[38]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Humbert,et al.  Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. , 2008, Human molecular genetics.

[40]  G. Watkins,et al.  Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. , 2004, European journal of cancer.

[41]  I. Macara,et al.  The Par3/aPKC interaction is essential for end bud remodeling and progenitor differentiation during mammary gland morphogenesis. , 2009, Genes & development.